ClinicalTrials.gg

Program

zadavotide guraxetan

Also written as “FPI-2265” and “AZD2265 (FPI-2265)”.

Its studies are mostly in Prostatic Neoplasms, led by AstraZeneca.

Furthest: phase 2, since Dec 20, 20214 company-led studies, 4 open or runningNext primary completion: Dec 23, 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca44 open or runningphase 2since Dec 20, 2021Dec 20, 2021Dec 23, 2026phase 2 · NCT06402331
  • Named in AstraZeneca’s own pipeline as zadavotide guraxetan (AZD2265), phase 3, as of Oct 30, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 20, 2021First study: phase 2 study in Metastatic Castration Resistant Prostate CancerFirst studyNCT05219500 · 115 enrolled · United States
  2. Apr 26, 2024Phase 2 study in Metastatic Castration-resistant Prostate CancerNCT06402331 · 110 enrolled · United States
  3. Mar 21, 2025Phase 2 study in Metastatic Castration-resistant Prostate CancerNCT06909825 · 85 enrolled · Australia
  4. May 11, 2026Phase 2 study in Prostatic NeoplasmsNCT07590934 · 152 planned · United States, Australia, Germany and more

Ahead

  1. Dec 23, 2026Primary completion: phase 2 study in Metastatic Castration-resistant Prostate CancerNCT06402331
  2. May 2027Primary completion: phase 2 study in Metastatic Castration-resistant Prostate CancerNCT06909825
  3. Sep 25, 2029Primary completion: phase 2 study in Prostatic NeoplasmsNCT07590934

TargetBeta

“A radioconjugate composed of zadavotide guraxetan, a human prostate-specific membrane antigen (PSMA)-targeting ligand linked to the bifunctional macrocyclic chelating agent 1,4,7,10-tetraazacyclododecane-1-(glutamic acid)-4,7,10-triacetic acid (DOTAGA; DOTA-GA), and conjugated to the alpha-emitti…”NCIt, read by Claude
“A radioconjugate composed of zadavotide guraxetan, a human prostate-specific membrane antigen (PSMA)-targeting ligand ”NCIt, by rule

Other programs on FOLH1

ProgramCompanyFurthest phaseStudies
flotufolastat F 18ruleBraccophase 47
piflufolastatruleLantheusphase 45
abefolastat tesaroxetan CU-64ruleclarity-pharmaceuticals-ltdphase 35
gallium 68 PSMA-11ruleNovartisphase 34
Lutetium Lu 177 Ludotadipeprulefuturechemphase 33
Anti-PSMA/Anti-CD28 Bispecific Antibody JNJ-87189401Johnson & Johnsonphase 32
Lutetium Lu 177 NYM032ruleNorroy Biosciencephase 32
actinium AC-225 vipivotide tetraxetanNovartisphase 32
HRS-4357Jiangsu HengRui Medicinephase 32
AB-001rulefrontier-biotechnologies-incphase 23
olsutamigruleRegeneron Pharmaceuticalsphase 22
SHR-4394Jiangsu HengRui Medicinephase 22

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07590934Prostatic Neoplasms · United States, Australia, Germany and more2RecruitingSep 25, 2029152
NCT06909825Metastatic Castration-resistant Prostate Cancer · Australia2Active, not recruitingMay 202785
NCT06402331Metastatic Castration-resistant Prostate Cancer · United States2Active, not recruitingDec 23, 2026110
NCT05219500Metastatic Castration Resistant Prostate Cancer · United States2Active, not recruitingMay 30, 2025115

How it is read

Names in the registry

  • “FPI-2265”, 3 entries
  • “AZD2265 (FPI-2265)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.